A recent preclinical study with an AXL-targeted ADC conjugated to a pyrrolobenzodiazepine cytotoxin showed potentially promising results in a BRCA1-mutated ovarian cancer model, highlighting the potential benefit of ADCs with varied mechanisms of action (38). Here, BRCA1 is linked to ovarian cancer.